Arcutis Biotherapeutics granted an aggregate of 62,500 restricted stock units covering its common stock to six newly hired employees, with a grant date of October 1, 2026. The awards were approved by the Compensation Committee of Arcutis’ Board of Directors under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan as material employment inducements and in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% vesting on each annual anniversary of the vesting commencement date, subject to continued employment. Arcutis is a commercial-stage medical dermatology company focused on chronic inflammatory skin diseases and says it has developed a portfolio of advanced targeted topicals approved for three major inflammatory skin diseases.